Balicatib Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 397

Clinical Trials

The clinical evaluation of Balicatib includes a completed Phase 2 trial sponsored by Novartis Pharmaceuticals to assess the safety and efficacy of the investigational drug in postmenopausal women with osteopenia or osteoporosis. With recruitment officially concluded, this study represents a focused, industry-sponsored research initiative dedicated to evaluating the drug's therapeutic potential in metabolic bone conditions.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00170911	Completed	Osteoporosis	Novartis Pharmaceuticals\|Novartis	2005-03	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Balicatib product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Balicatib selectively binds to and inhibits cathepsin K, thereby blocking the downstream enzymatic cleavage of collagen and suppressing osteoclast-mediated bone matrix degradation. This inhibition of bone resorption preserves overall bone structural integrity and mineral density, establishing the mechanistic basis for its therapeutic evaluation in clinical conditions such as osteoporosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).